{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:39:00Z","timestamp":1790246340324,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014481","name":"Kite Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014481","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100014561","name":"Juno Therapeutics, Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014561","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.hoc.2020.06.010","type":"journal-article","created":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T13:02:23Z","timestamp":1596286943000},"page":"957-970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Jordan","family":"Gauthier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.hoc.2020.06.010_bib1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.24797","article-title":"Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management","volume":"92","author":"Vose","year":"2017","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.010_bib2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A\u00a0new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.010_bib3","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/sj.leu.2402272","article-title":"Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype","volume":"15","author":"Bernard","year":"2001","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.hoc.2020.06.010_bib4","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma","volume":"377","author":"Gouill","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.010_bib5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.010_bib6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.15411","article-title":"Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"182","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.010_bib7","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","author":"Rule","year":"2018","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.010_bib8","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bjh.15723","article-title":"Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma","volume":"184","author":"Rule","year":"2018","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.010_bib9","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2020.06.010_bib10","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.010_bib11","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.bbmt.2015.05.010","article-title":"The impact of graft-versus-host disease on the relapse rate in patients with lymphoma depends on the histological subtype and the intensity of the conditioning regimen","volume":"21","author":"Urbano-Ispizua","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.010_bib12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2014.223","article-title":"The EBMT\/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma","volume":"29","author":"Robinson","year":"2014","journal-title":"Leukemia"},{"issue":"12S","key":"10.1016\/j.hoc.2020.06.010_bib13","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/j.bulcan.2017.06.020","article-title":"Allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques dans la lymphome de Hodgkin, le lymphome du manteau et autres h\u00e9mopathies lympho\u00efdes rares : recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)","volume":"104","author":"Gauthier","year":"2017","journal-title":"Bull Cancer"},{"issue":"18","key":"10.1016\/j.hoc.2020.06.010_bib14","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.010_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","article-title":"Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality","volume":"32","author":"Fenske","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.010_bib16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41409-018-0207-4","article-title":"Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties","volume":"54","author":"Dreger","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"22","key":"10.1016\/j.hoc.2020.06.010_bib17","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.2217\/fon-2016-0146","article-title":"Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review","volume":"12","author":"Kharfan-Dabaja","year":"2016","journal-title":"Future Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2020.06.010_bib18","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.bbmt.2015.07.012","article-title":"Phase II study of nonmyeloablative allogeneic bone marrow transplantation for B cell lymphoma with post-transplantation rituximab and donor selection based first on non-HLA factors","volume":"21","author":"Kanakry","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.hoc.2020.06.010_bib19","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2\u00a0Gy total body irradiation for relapsed and refractory mantle cell lymphoma","volume":"104","author":"Maris","year":"2004","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.hoc.2020.06.010_bib20","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.29498","article-title":"Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"121","author":"Vaughn","year":"2015","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.010_bib21","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/bmt.2015.156","article-title":"Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era","volume":"50","author":"Mussetti","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.010_bib22","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/bjh.15721","article-title":"Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations","volume":"184","author":"Lin","year":"2018","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.010_bib23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"10.1016\/j.hoc.2020.06.010_bib24","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a center for international blood and marrow transplant research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2020.06.010_bib25","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"issue":"355","key":"10.1016\/j.hoc.2020.06.010_bib26","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor\u2013modified T\u00a0cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"26","key":"10.1016\/j.hoc.2020.06.010_bib27","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.06.010_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.010_bib29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.010_bib30","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR\u2013T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"26","key":"10.1016\/j.hoc.2020.06.010_bib31","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor\u2013modified T\u00a0cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.06.010_bib32","series-title":"Pivotal safety and efficacy results from Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed\/refractory (R\/R) large B cell lymphomas","author":"Abramson","year":"2019"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.010_bib33","doi-asserted-by":"crossref","first-page":"e1049","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clinical & Translational Immunology"},{"issue":"suppl 1","key":"10.1016\/j.hoc.2020.06.010_bib34","article-title":"754 KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T\u00a0cell therapy, in patients (Pts) with relapsed\/refractory (R\/R) mantle cell lymphoma (MCL): results of the Phase 2 ZUMA-2 study","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.010_bib35","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2020.06.010_bib36","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.010_bib37","doi-asserted-by":"crossref","unstructured":"Wang M, Gordon LI, Palomba ML, et\u00a0al. Safety and preliminary efficacy in patients (pts) with relapsed\/refractory (R\/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (Liso-cel) in TRANSCEND NHL 001. J Clin Oncol (ASCO Abstract) 2019;37(15):7516.","DOI":"10.1200\/JCO.2019.37.15_suppl.7516"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:13:44Z","timestamp":1760184824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820300733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0889858820300733"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.06.010","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}